Opendata, web and dolomites

RNAmpMax SIGNED

Maximization of amplification of next-generation RNA replicon vaccines through synergistic molecular and formulation design

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RNAmpMax project word cloud

Explore the words cloud of the RNAmpMax project. It provides you a very rough idea of what is the project "RNAmpMax" about.

maria    london    amplification    reflects    restricts    co    demonstration    institutet    mirror    incorporates    designed    nonhuman    initial    penetration    clinical    primates    linear    have    worldwide    imperial    generation    formulated    inhibits    as    minimize    fellow    replicons    limiting    oligonucleotides    messenger    intend    shattock    world    leader    stevens    excellent    nucleic    secondment    molly    prof    edge    translational    platform    interferon    disparity    protein    localization    scalability    possess    synthesized    orders    molecular    polymeric    biomaterials    curie    overcome    vaccines    synthetic    modifications    demonstrated    mice    inhibit    nucleus    robin    plasmid    maximizing    strand    acid    adaptions    doses    sk    relationship    efficient    rna    cascade    synergistic    magnitude    dna    mrna    self    supervision    combination    therapeutics    engineer    college    expression    pdna    cutting    karolinska    tested    odowska    first    paired    dose    polyplex    formulation    trials    scaled    polymer    single    barrier    affordable   

Project "RNAmpMax" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-02   to  2021-01-01

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 183˙454.00

Map

 Project objective

As a Maria Skłodowska-Curie Fellow, I aim to develop formulated next-generation RNA replicons that are designed to overcome the limiting initial type I interferon response that inhibits amplification and protein expression. RNA replicons are currently a cutting edge nucleic acid platform for delivery of vaccines and therapeutics, as they do not require penetration into the nucleus like plasmid DNA, but possess self-amplification properties that results in more efficient protein expression than messenger RNA. While pDNA and mRNA have have demonstrated excellent results with low doses when tested in mice doses must be scaled up by two orders of magnitude to mirror these effects in nonhuman primates. This disparity reflects a non-linear dose-response relationship, where increased doses are associated with triggering of an interferon cascade which restricts protein expression. Under the supervision of Prof. Robin Shattock, a world leader in translational vaccines and clinical trials at Imperial College London, I aim to overcome this translational barrier for RNA replicons by focusing on maximizing protein expression. I intend to engineer synergistic increases in the amplification of RNA replicons through a combination of molecular modifications designed to minimize interferon response and co-delivery with synthetic single-strand oligonucleotides known to inhibit the interferon pathway. These molecular adaptions will be paired with a novel delivery polymer that directly incorporates oligonucleotides into the RNA polyplex, thus ensuring co-localization: to be synthesized in collaboration with Prof. Molly Stevens, a world leader in polymeric biomaterials, during a secondment at the Karolinska Institutet. This project is the first demonstration of synergistic molecular and formulation design to address the non-linear dose-response relationship, and could impact scalability of RNA vaccines and therapeutics making them more affordable and available in Europe and worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RNAMPMAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RNAMPMAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More  

FARMACCOUNTA (2019)

Farm Accountancy Data as a Source for the History of European Agriculture

Read More  

GENESE 17 (2018)

Geometries of Exotic NuclEar StructurE 17

Read More